Quality of radiotherapy reporting in randomized controlled trials of prostate cancer
Abstract Background Good radiotherapy reporting in clinical trials of prostate radiotherapy is important because it will allow accurate reproducibility of radiotherapy treatment and minimize treatment variations that can affect patient outcomes. The aim of our study is to assess the quality of prost...
Main Authors: | Yu Yang Soon, Desiree Chen, Teng Hwee Tan, Jeremy Tey |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13014-018-1053-7 |
Similar Items
-
Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials
by: Yin Z, et al.
Published: (2019-02-01) -
Investigating the impact of open label design on patient‐reported outcome results in prostate cancer randomized controlled trials
by: Guillaume Mouillet, et al.
Published: (2020-10-01) -
Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial
by: Lips Irene M, et al.
Published: (2011-12-01) -
Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
by: Wei Guo, et al.
Published: (2019-11-01) -
Quality of reporting of randomized controlled trials in ten academic Indian dental journals
by: Sudhakar Vundavalli, et al.
Published: (2016-01-01)